Barclays reiterated coverage on SpringWorks Therapeutics with a new price target

2/26/21 7:31:16 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Barclays reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $105.00 from $92.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SWTX

Date	Price Target	Rating	Analyst
11/20/2024	$60.00	Outperform	Evercore ISI
2/5/2024	$75.00	Buy	Guggenheim
12/1/2022	$45.00	Buy	BofA Securities
9/8/2021	$97.00 → $105.00	Overweight	JP Morgan
8/5/2021	$136.00 → $137.00	Buy	HC Wainwright & Co.